Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Life Sciences
Cholesterol Conjugated Hdac Inhibitor As Novel Anticancer Agent, Paul Orefice, Jane Peterson, Bin Sun
Cholesterol Conjugated Hdac Inhibitor As Novel Anticancer Agent, Paul Orefice, Jane Peterson, Bin Sun
Undergraduate Research Posters 2014
Histone deacetylase (HDAC) inhibitors are a class of promising new multifunctional anticancer agents. These agents are able to affect multiple epigenetic changes in aberrant cells. In addition to regulating the gene expression and transcription via chromatin remodeling, HDAC inhibitors can also modulate a variety of cellular functions including proliferation, differentiation, and apoptosis. Vorinostat (SuberAniloHydroxamic Acid, SAHA), the first HDAC inhibitor approved by FDA, inhibited the metastasis of various cancer cells. However, SAHA distributes in cancer tissue and normal tissue in a similar level. It will be ideal to selectively delivery SAHA into cancer cells. Rapidly growing cancer cells have a …